| pubmed-article:14967727 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14967727 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:14967727 | lifeskim:mentions | umls-concept:C0007194 | lld:lifeskim |
| pubmed-article:14967727 | lifeskim:mentions | umls-concept:C0054015 | lld:lifeskim |
| pubmed-article:14967727 | lifeskim:mentions | umls-concept:C0231220 | lld:lifeskim |
| pubmed-article:14967727 | lifeskim:mentions | umls-concept:C1442792 | lld:lifeskim |
| pubmed-article:14967727 | lifeskim:mentions | umls-concept:C1510438 | lld:lifeskim |
| pubmed-article:14967727 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:14967727 | pubmed:dateCreated | 2004-3-2 | lld:pubmed |
| pubmed-article:14967727 | pubmed:abstractText | Hypertrophic cardiomyopathy (HCM) has a diverse clinical spectrum that often includes progressive heart failure symptoms and disability. Assessment of symptom severity may be highly subjective, encumbered by the heterogeneous clinical presentation. Plasma B-type natriuretic peptide (BNP) has been used widely as an objective marker for heart failure severity and outcome, predominantly in coronary heart disease with ventricular dilatation and systolic dysfunction. | lld:pubmed |
| pubmed-article:14967727 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14967727 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14967727 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14967727 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:14967727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14967727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14967727 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14967727 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:14967727 | pubmed:issn | 1524-4539 | lld:pubmed |
| pubmed-article:14967727 | pubmed:author | pubmed-author:MaronBarry... | lld:pubmed |
| pubmed-article:14967727 | pubmed:author | pubmed-author:CaseySusan... | lld:pubmed |
| pubmed-article:14967727 | pubmed:author | pubmed-author:CohnJay NJN | lld:pubmed |
| pubmed-article:14967727 | pubmed:author | pubmed-author:DuprezDanielD | lld:pubmed |
| pubmed-article:14967727 | pubmed:author | pubmed-author:AeppliDorothe... | lld:pubmed |
| pubmed-article:14967727 | pubmed:author | pubmed-author:Tholakanahall... | lld:pubmed |
| pubmed-article:14967727 | pubmed:author | pubmed-author:ZenovichAndre... | lld:pubmed |
| pubmed-article:14967727 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:14967727 | pubmed:day | 2 | lld:pubmed |
| pubmed-article:14967727 | pubmed:volume | 109 | lld:pubmed |
| pubmed-article:14967727 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14967727 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14967727 | pubmed:pagination | 984-9 | lld:pubmed |
| pubmed-article:14967727 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:meshHeading | pubmed-meshheading:14967727... | lld:pubmed |
| pubmed-article:14967727 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14967727 | pubmed:articleTitle | Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. | lld:pubmed |
| pubmed-article:14967727 | pubmed:affiliation | Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, and University of Minnesota, Minneapolis, MN 55407, USA. hcm.maron@mhif.org | lld:pubmed |
| pubmed-article:14967727 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14967727 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14967727 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14967727 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14967727 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14967727 | lld:pubmed |
